Wilson Sonsini Goodrich & Rosati advised Sirius on patent matters related to the transaction. CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...
CRISPR Therapeutics’ Multi-Target Collaboration with Sirius Therapeutics
Sirius Therapeutics’ $50 Million Series B2 Financing Round
Wilson Sonsini Goodrich & Rosati advised Sirius Therapeutics on patent matters related to the transaction. Biotechnology company Sirius Therapeutics (Sirius) announced that it has completed nearly...


























